Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 44

1.

Adding the Team into T1 Translational Research: A Case Study of Multidisciplinary Team Science in the Evaluation of Biomarkers of Prostate Cancer Risk and Prognosis.

Marrone MT, Joshu CE, Peskoe SB, De Marzo AM, Heaphy CM, Lupold SE, Meeker AK, Platz EA.

Clin Chem. 2018 Dec 5. pii: clinchem.2018.293365. doi: 10.1373/clinchem.2018.293365. [Epub ahead of print]

PMID:
30518666
2.

PDCD4 is an androgen-repressed tumor suppressor that regulates prostate cancer growth and castration resistance.

Zennami K, Choi SM, Liao R, Li Y, Dinalankara W, Marchionni L, Rafiqi FH, Kurozumi A, Hatano K, Lupold SE.

Mol Cancer Res. 2018 Dec 5. pii: molcanres.0837.2018. doi: 10.1158/1541-7786.MCR-18-0837. [Epub ahead of print]

PMID:
30518628
3.

Cell-type specific expression of oncogenic and tumor suppressive microRNAs in the human prostate and prostate cancer.

Kumar B, Rosenberg AZ, Choi SM, Fox-Talbot K, De Marzo AM, Nonn L, Brennen WN, Marchionni L, Halushka MK, Lupold SE.

Sci Rep. 2018 May 8;8(1):7189. doi: 10.1038/s41598-018-25320-z.

4.

Aptamers and apple pies: a mini-review of PSMA aptamers and lessons from Donald S. Coffey.

Lupold SE.

Am J Clin Exp Urol. 2018 Apr 1;6(2):78-86. eCollection 2018. Review.

5.

The orally active pterocarpanquinone LQB-118 exhibits cytotoxicity in prostate cancer cell and tumor models through cellular redox stress.

Martino T, Kudrolli TA, Kumar B, Salviano I, Mencalha A, Coelho MGP, Justo G, Costa PRR, Sabino KCC, Lupold SE.

Prostate. 2018 Feb;78(2):140-151. doi: 10.1002/pros.23455. Epub 2017 Nov 6.

PMID:
29105806
6.

Differential long-term stability of microRNAs and RNU6B snRNA in 12-20 year old archived formalin-fixed paraffin-embedded specimens.

Peskoe SB, Barber JR, Zheng Q, Meeker AK, De Marzo AM, Platz EA, Lupold SE.

BMC Cancer. 2017 Jan 6;17(1):32. doi: 10.1186/s12885-016-3008-4.

7.

Identification of miR-30b-3p and miR-30d-5p as direct regulators of androgen receptor signaling in prostate cancer by complementary functional microRNA library screening.

Kumar B, Khaleghzadegan S, Mears B, Hatano K, Kudrolli TA, Chowdhury WH, Yeater DB, Ewing CM, Luo J, Isaacs WB, Marchionni L, Lupold SE.

Oncotarget. 2016 Nov 8;7(45):72593-72607. doi: 10.18632/oncotarget.12241.

8.

Development and Application of a Novel Model System to Study "Active" and "Passive" Tumor Targeting.

Mukherjee A, Kumar B, Hatano K, Russell LM, Trock BJ, Searson PC, Meeker AK, Pomper MG, Lupold SE.

Mol Cancer Ther. 2016 Oct;15(10):2541-2550. Epub 2016 Aug 2.

9.

MicroRNA expression and function in prostate cancer: a review of current knowledge and opportunities for discovery.

Kumar B, Lupold SE.

Asian J Androl. 2016 Jul-Aug;18(4):559-67. doi: 10.4103/1008-682X.177839. Review.

10.

Characterization of a novel metastatic prostate cancer cell line of LNCaP origin.

Castanares MA, Copeland BT, Chowdhury WH, Liu MM, Rodriguez R, Pomper MG, Lupold SE, Foss CA.

Prostate. 2016 Feb;76(2):215-25. doi: 10.1002/pros.23115. Epub 2015 Oct 26.

11.

Systemic Administration and Targeted Radiosensitization via Chemically Synthetic Aptamer-siRNA Chimeras in Human Tumor Xenografts.

Ni X, Zhang Y, Zennami K, Castanares M, Mukherjee A, Raval RR, Zhou H, DeWeese TL, Lupold SE.

Mol Cancer Ther. 2015 Dec;14(12):2797-804. doi: 10.1158/1535-7163.MCT-15-0291-T. Epub 2015 Oct 5.

12.

A functional screen identifies miRNAs that inhibit DNA repair and sensitize prostate cancer cells to ionizing radiation.

Hatano K, Kumar B, Zhang Y, Coulter JB, Hedayati M, Mears B, Ni X, Kudrolli TA, Chowdhury WH, Rodriguez R, DeWeese TL, Lupold SE.

Nucleic Acids Res. 2015 Apr 30;43(8):4075-86. doi: 10.1093/nar/gkv273. Epub 2015 Apr 6.

13.

Real-time, near-infrared fluorescence imaging with an optimized dye/light source/camera combination for surgical guidance of prostate cancer.

Neuman BP, Eifler JB, Castanares M, Chowdhury WH, Chen Y, Mease RC, Ma R, Mukherjee A, Lupold SE, Pomper MG, Rodriguez R.

Clin Cancer Res. 2015 Feb 15;21(4):771-80. doi: 10.1158/1078-0432.CCR-14-0891. Epub 2014 Dec 12.

14.

Investigation of miR-21, miR-141, and miR-221 expression levels in prostate adenocarcinoma for associated risk of recurrence after radical prostatectomy.

Zheng Q, Peskoe SB, Ribas J, Rafiqi F, Kudrolli T, Meeker AK, De Marzo AM, Platz EA, Lupold SE.

Prostate. 2014 Dec;74(16):1655-62. doi: 10.1002/pros.22883. Epub 2014 Sep 22.

15.

A novel approach for detecting viable and tissue-specific circulating tumor cells through an adenovirus-based reporter vector.

Wu P, Sokoll LJ, Kudrolli TA, Chowdhury WH, Ma R, Liu MM, Rodriguez R, Lupold SE.

Prostate. 2014 Sep;74(13):1286-1296. doi: 10.1002/pros.22845. Epub 2014 Jul 25.

16.

Evaluation of prostate-specific membrane antigen as an imaging reporter.

Castanares MA, Mukherjee A, Chowdhury WH, Liu M, Chen Y, Mease RC, Wang Y, Rodriguez R, Lupold SE, Pomper MG.

J Nucl Med. 2014 May;55(5):805-11. doi: 10.2967/jnumed.113.134031. Epub 2014 Apr 3.

17.

Correlation of Sprouty1 and Jagged1 with aggressive prostate cancer cells with different sensitivities to androgen deprivation.

Terada N, Shiraishi T, Zeng Y, Aw-Yong KM, Mooney SM, Liu Z, Takahashi S, Luo J, Lupold SE, Kulkarni P, Getzenberg RH.

J Cell Biochem. 2014 Sep;115(9):1505-15. doi: 10.1002/jcb.24805.

18.

Development and screening of a series of antibody-conjugated and silica-coated iron oxide nanoparticles for targeting the prostate-specific membrane antigen.

Mukherjee A, Darlington T, Baldwin R, Holz C, Olson S, Kulkarni P, DeWeese TL, Getzenberg RH, Ivkov R, Lupold SE.

ChemMedChem. 2014 Jul;9(7):1356-60. doi: 10.1002/cmdc.201300549. Epub 2014 Mar 3.

19.

Monitoring nanoparticle-mediated cellular hyperthermia with a high-sensitivity biosensor.

Mukherjee A, Castanares M, Hedayati M, Wabler M, Trock B, Kulkarni P, Rodriguez R, Getzenberg RH, DeWeese TL, Ivkov R, Lupold SE.

Nanomedicine (Lond). 2014 Dec;9(18):2729-43. doi: 10.2217/nnm.13.207.

20.

Bicalutamide-activated oncolytic adenovirus for the adjuvant therapy of high-risk prostate cancer.

Johnson TJ, Höti N, Liu C, Chowdhury WH, Li Y, Zhang Y, Lupold SE, Deweese T, Rodriguez R.

Cancer Gene Ther. 2013 Jul;20(7):394-402. doi: 10.1038/cgt.2013.34. Epub 2013 Jun 14.

21.

Mechanism of growth inhibition of prostate cancer xenografts by valproic acid.

Sidana A, Wang M, Shabbeer S, Chowdhury WH, Netto G, Lupold SE, Carducci M, Rodriguez R.

J Biomed Biotechnol. 2012;2012:180363. doi: 10.1155/2012/180363. Epub 2012 Oct 2.

22.

A real time Metridia luciferase based non-invasive reporter assay of mammalian cell viability and cytotoxicity via the β-actin promoter and enhancer.

Lupold SE, Johnson T, Chowdhury WH, Rodriguez R.

PLoS One. 2012;7(5):e36535. doi: 10.1371/journal.pone.0036535. Epub 2012 May 9.

23.

A novel source for miR-21 expression through the alternative polyadenylation of VMP1 gene transcripts.

Ribas J, Ni X, Castanares M, Liu MM, Esopi D, Yegnasubramanian S, Rodriguez R, Mendell JT, Lupold SE.

Nucleic Acids Res. 2012 Aug;40(14):6821-33. doi: 10.1093/nar/gks308. Epub 2012 Apr 13.

24.

Sequential SPECT and optical imaging of experimental models of prostate cancer with a dual modality inhibitor of the prostate-specific membrane antigen.

Banerjee SR, Pullambhatla M, Byun Y, Nimmagadda S, Foss CA, Green G, Fox JJ, Lupold SE, Mease RC, Pomper MG.

Angew Chem Int Ed Engl. 2011 Sep 19;50(39):9167-70. doi: 10.1002/anie.201102872. Epub 2011 Aug 22. No abstract available.

25.

Nucleic acid aptamers: clinical applications and promising new horizons.

Ni X, Castanares M, Mukherjee A, Lupold SE.

Curr Med Chem. 2011;18(27):4206-14. Review.

26.

Prostate-targeted radiosensitization via aptamer-shRNA chimeras in human tumor xenografts.

Ni X, Zhang Y, Ribas J, Chowdhury WH, Castanares M, Zhang Z, Laiho M, DeWeese TL, Lupold SE.

J Clin Invest. 2011 Jun;121(6):2383-90. doi: 10.1172/JCI45109. Epub 2011 May 9.

27.

Does valproic acid induce neuroendocrine differentiation in prostate cancer?

Sidana A, Wang M, Chowdhury WH, Toubaji A, Shabbeer S, Netto G, Carducci M, Lupold SE, Rodriguez R.

J Biomed Biotechnol. 2011;2011:607480. doi: 10.1155/2011/607480. Epub 2010 Oct 25.

28.

Adenovirus targeting to prostate-specific membrane antigen through virus-displayed, semirandom peptide library screening.

Wu P, Kudrolli TA, Chowdhury WH, Liu MM, Rodriguez R, Lupold SE.

Cancer Res. 2010 Dec 1;70(23):9549-53. doi: 10.1158/0008-5472.CAN-10-1760. Epub 2010 Jul 29.

29.

Armoring CRAds with p21/Waf-1 shRNAs: the next generation of oncolytic adenoviruses.

Höti N, Chowdhury WH, Mustafa S, Ribas J, Castanares M, Johnson T, Liu M, Lupold SE, Rodriguez R.

Cancer Gene Ther. 2010 Aug;17(8):585-97. doi: 10.1038/cgt.2010.15. Epub 2010 May 7.

30.

Evaluation of continuous low dose rate versus acute single high dose rate radiation combined with oncolytic viral therapy for prostate cancer.

Liu C, Zhang Y, Liu MM, Zhou H, Chowdhury W, Lupold SE, Deweese TL, Rodriguez R.

Int J Radiat Biol. 2010 Mar;86(3):220-9. doi: 10.3109/09553000903419338.

31.

The transcriptional regulation of miR-21, its multiple transcripts, and their implication in prostate cancer.

Ribas J, Lupold SE.

Cell Cycle. 2010 Mar 1;9(5):923-9. Epub 2010 Mar 11. Review.

32.

miR-21: an androgen receptor-regulated microRNA that promotes hormone-dependent and hormone-independent prostate cancer growth.

Ribas J, Ni X, Haffner M, Wentzel EA, Salmasi AH, Chowdhury WH, Kudrolli TA, Yegnasubramanian S, Luo J, Rodriguez R, Mendell JT, Lupold SE.

Cancer Res. 2009 Sep 15;69(18):7165-9. doi: 10.1158/0008-5472.CAN-09-1448. Epub 2009 Sep 8.

33.

Radiohalogenated prostate-specific membrane antigen (PSMA)-based ureas as imaging agents for prostate cancer.

Chen Y, Foss CA, Byun Y, Nimmagadda S, Pullambhatla M, Fox JJ, Castanares M, Lupold SE, Babich JW, Mease RC, Pomper MG.

J Med Chem. 2008 Dec 25;51(24):7933-43. doi: 10.1021/jm801055h.

34.

Synthesis and evaluation of technetium-99m- and rhenium-labeled inhibitors of the prostate-specific membrane antigen (PSMA).

Banerjee SR, Foss CA, Castanares M, Mease RC, Byun Y, Fox JJ, Hilton J, Lupold SE, Kozikowski AP, Pomper MG.

J Med Chem. 2008 Aug 14;51(15):4504-17. doi: 10.1021/jm800111u. Epub 2008 Jul 19.

35.

A novel method for generating and screening peptides and libraries displayed on adenovirus fiber.

Lupold SE, Kudrolli TA, Chowdhury WH, Wu P, Rodriguez R.

Nucleic Acids Res. 2007;35(20):e138. Epub 2007 Oct 26.

36.

Androgen receptor attenuation of Ad5 replication: implications for the development of conditionally replication competent adenoviruses.

Höti N, Li Y, Chen CL, Chowdhury WH, Johns DC, Xia Q, Kabul A, Hsieh JT, Berg M, Ketner G, Lupold SE, Rodriguez R.

Mol Ther. 2007 Aug;15(8):1495-503. Epub 2007 Jun 12.

37.

Valproic acid, a histone deacetylase inhibitor, is an antagonist for oncolytic adenoviral gene therapy.

Höti N, Chowdhury W, Hsieh JT, Sachs MD, Lupold SE, Rodriguez R.

Mol Ther. 2006 Dec;14(6):768-78. Epub 2006 Sep 20.

38.

Adenoviral gene therapy, radiation, and prostate cancer.

Lupold SE, Rodriguez R.

Rev Urol. 2005 Fall;7(4):193-202.

39.

Valproic acid inhibits invasiveness in bladder cancer but not in prostate cancer cells.

Chen CL, Sung J, Cohen M, Chowdhury WH, Sachs MD, Li Y, Lakshmanan Y, Yung BY, Lupold SE, Rodriguez R.

J Pharmacol Exp Ther. 2006 Nov;319(2):533-42. Epub 2006 Jul 25.

40.
41.

Identification and characterization of nuclease-stabilized RNA molecules that bind human prostate cancer cells via the prostate-specific membrane antigen.

Lupold SE, Hicke BJ, Lin Y, Coffey DS.

Cancer Res. 2002 Jul 15;62(14):4029-33. Erratum in: Cancer Res. 2012 Aug 1;72(15):3887.

42.

The XPB and XPD DNA helicases are components of the p53-mediated apoptosis pathway.

Wang XW, Vermeulen W, Coursen JD, Gibson M, Lupold SE, Forrester K, Xu G, Elmore L, Yeh H, Hoeijmakers JH, Harris CC.

Genes Dev. 1996 May 15;10(10):1219-32.

43.

Nitric oxide-induced p53 accumulation and regulation of inducible nitric oxide synthase expression by wild-type p53.

Forrester K, Ambs S, Lupold SE, Kapust RB, Spillare EA, Weinberg WC, Felley-Bosco E, Wang XW, Geller DA, Tzeng E, Billiar TR, Harris CC.

Proc Natl Acad Sci U S A. 1996 Mar 19;93(6):2442-7.

44.

Effects of p53 mutants on wild-type p53-mediated transactivation are cell type dependent.

Forrester K, Lupold SE, Ott VL, Chay CH, Band V, Wang XW, Harris CC.

Oncogene. 1995 Jun 1;10(11):2103-11.

PMID:
7784055

Supplemental Content

Loading ...
Support Center